M3 Biotechnology Secures $1.4M from Alzheimer’s Drug Discovery Foundation to Launch Clinical Trials for Innovative Alzheimer's Therapy

Seattle-based M3 Biotechnology secured an additional $1.4 million from the Alzheimer’s Drug Discovery Foundation to prepare clinical trials for its novel Alzheimer’s therapy aimed at stopping neuron deterioration. This funding follows a previous $14 million raised, supporting the company’s advancement toward potentially halting disease progression rather than just treating symptoms.